theMednetRegister

Radiation Oncology

Prostate Cancer   

Questions discussed in this category

What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?
8 Answers available
Do you offer RT both to the prostate and synchronous oligometastases in de novo oligometastatic prostate cancer?
If a patient presents with de novo oligometastatic (i.e., meeting STAMPEDE low met burden criteria) prostate cancer with no prior history of primary t...
5 Answers available
Given the PATRIOT trial and hypo-FLAME 2.0, do you consider once-a-week prostate SBRT instead of every other day?
1 Answer available
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
For example, if MRI revealed prostate-confined disease but PSMA had moderate avidity in the bilateral seminal vesicles, would you obtain further biops...
3 Answers available
Which patients with prostate cancer do you consider to be good candidates for salvage local treatment after radiation therapy?
How does time since radiation, original PSA and grade group/gleason score inform your decision? 
2 Answers available
What is your approach to a patient with prostate cancer with suspicion of rectal wall invasion but otherwise localized disease?
Would you treat this patient any differently than any other very high risk prostate cancer patient? Are there any additional dose constraints for the ...
3 Answers available
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
Would you consider adding docetaxel to ADT and novel hormonal agents?
4 Answers available
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
FDG PET, Axumin PET, Bone scan? Or just proceed with salvage ADT/RT?
4 Answers available
What are your top takeaways in GU Cancers from ASTRO 2024?
6 Answers available
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
2 Answers available
How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?
With the recent publication of PSMAfore, what are your current criteria for offering Lu-177 therapy?
1 Answer available
As PARTIQoL was a negative study, what is the current role for proton therapy in the management of prostate cancer patients?
The study showed no benefit in terms of cancer control or toxicity. There was a significant finding of worse sexual function, but this was deemed to b...
2 Answers available
How would you plan sequencing of an MRI-directed prostate nodule micro-boost when doing a sequential plan?
If pursuing a sequential approach with boost to dominant prostate nodules as seen on MRI, what dosing and fractionation would you use in the initial a...
3 Answers available
In asymptomatic patients with castrate resistant prostate cancer who have failed chemotherapy and have progressive vertebral body metastases, when do you prescribe lutetium-177 vs prophylactic spinal radiation?
Should external beam radiation be 'maxed out' before use of lutetium-177?
3 Answers available
Under what circumstances would you treat prostate cancer without a biopsy?
Would you be willing to treat an elderly patient on blood thinners who has PSMA+ PET, elevated PSA, and multiple urologists have deemed biopsy too ris...
2 Answers available
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
If delivering 300 cGy per fraction to the DIL, what urethra dose constraints to you use for 26 and 28 fraction regimens?
3 Answers available
In what situations would a standard FDG PET/CT be useful in the evaluation of high risk prostate cancer?
With the advent of PSMA PET/CT, this is my study of choice for high risk prostate cancer. Are there scenarios where standard FDG PET is useful? For ex...
4 Answers available
What radiation treatments would you offer an older man with unfavorable intermediate-risk prostate cancer, with comorbid conditions, if you don't feel he is a good candidate for full-course radiation therapy with ADT?
Would you consider 36 Gy in 6 once-weekly fractions?
4 Answers available
Would you consider re-irradiation for a prostate local failure for a patient who initially received standard fractionation with a focal SIB to 95 Gy, or a SBRT boost with cyberknife after EBRT?
What dose constraints are you most worried about in the re-irradiation setting with such high doses prior?
4 Answers available
How does prior prostate artery embolization impact your treatment recommendations for prostate cancer?
3 Answers available
Based on the recent guidelines, should prostate SBRT dose be no higher than 3625 cGy in 5 fractions?
The recently published executive summary from ASTRO/ASCO/AUA hypofractionated radiation therapy for localized prostate cancer states "Five-fracti...
3 Answers available
How do you counsel NCCN low and very low risk prostate cancer patients who receive a high risk DECIPHER score?
1 Answer available
When do you start ADT for a patient with a new diagnosis of node positive prostate cancer receiving radiation?
Do you start neoadjuvantly? Concurrently?
2 Answers available
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
Long-term ADT is deleterious to multiple organ systems (bone/sexual/psychiatric) and increases the risk of MACE. What level 1 evidence do we have to c...
2 Answers available
Why are patients getting enzalutamide s/p prostatectomy not candidates for salvage radiation therapy?
On the EMBARK trial (Freedland et al., PMID 37851874), 25% of men had a prostatectomy and the publication states, "Patients were excluded … if ...
2 Answers available
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
1 Answer available
Would you offer adjuvant XRT to the prostate fossa in a patient with Lynch Syndrome?
What fields? Would you treat the pelvis? What factors would help you determine this?
1 Answer available
In post-prostatectomy patients where urinary continence is never achieved, how and when would you plan RT when it is clinically indicated?
1 Answer available
Would you offer focal prostate boost per FLAME protocol for GTV defined by PET alone without MRI?
PSMA or Flucyclovine defined focal nodule
3 Answers available
What is your preferred dose to gross lymph nodes when treating non-metastatic high-risk prostate cancer?
NCCN, NRG contouring guidelines, and NRG-GU-009 all recommend treating non-metastatic high risk prostate cancer with dose escalation to involved gross...
7 Answers available
Has the recent presentation of RADICALS-HD changed your ADT duration recommendations for patients receiving post operative radiation therapy for prostate cancer after radical prostatectomy?
2 Answers available
Given RADICALS-HD, are you completing 24 mo vs 6 mo of ADT with XRT following RP?
RADICALS-HD trial (ESMO 2022) demonstrated metastasis free survival benefit with 24 months compared to 6 months of ADT.
1 Answer available
Would you ever omit or reduce prostate bed radiation in a post-prostatectomy patient who develops recurrence in pelvic LNs?
Which criteria/factors would you use to decide whether to de-intensify prostate bed/fossa treatment? For instance, surgical margin status or biochemic...
1 Answer available
Do you offer prostate RT to men with 0-3 bone metastases on conventional imaging when PSMA PET shows a very high number of M1 lesions?
STAMPEDE answer is yes, intuitively it seems there must be a line somewhere though. For patients staged only with PET that is widely M1, should a CT ...
4 Answers available
Are you comfortable combining relugolix with enzalutamide or abiraterone?
Current NCCN guidelines recommended not combining relugolix with these agents until more data is available.  Any drug interaction concerns or ot...
2 Answers available
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
2 Answers available
What criteria do you use when considering treating the pelvic nodes in a salvage prostatectomy case versus covering only the postoperative bed?
Would a specific Gleason score, age, pathological feature, or PSA be an indication for covering the pelvic nodes? Would giving concurrent ADT affect y...
3 Answers available
What are your preferred strategies to manage mild to moderate rectal ulceration causing tenesmus and discomfort after chemoradiation for rectal adenocarcinoma?
Or, to manage tenesmus and discomfort after any type of pelvic radiation.
1 Answer available
Can you give Pluvicto with concurrent palliative EBRT?
If so, do you modify your external beam dose? 
1 Answer available
Would you offer salvage radiation for a local recurrence of prostate cancer that was initially treated with SBRT?
How would poor urinary or bowel function affect the recommendation?
1 Answer available
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
Which patients specifically benefit from both mpMRI and PET-PSMA?
4 Answers available
Does the presence of ductal adenocarcinoma change how you risk stratify or treat patients with localized prostate cancer?
How would it change your risk group or management? Does Decipher help further inform treatment?
1 Answer available
Is it acceptable to use SBRT for prostate bed RT?
If so, what dose?
4 Answers available
Does a negative staging PSMA PET in a patient with biopsy-proven recurrent prostatic adenocarcinoma change your management?
I have a pair of patients with MRI+ and biopsy+ disease who have staging PSMA PET/CT that do not show disease within the prostate (or anywhere else).&...
2 Answers available
How do you manage hot flashes in men with prostate cancer on androgen deprivation therapy?
16 Answers available
Can you/do you use an androgen receptor blocker alone in patients with metastatic hormone-sensitive prostate cancer who cannot tolerate GnRH-directed therapy?
7 Answers available
How would you treat margin positive, node positive (pN+) prostate cancer with detectable post-op PSA but negative PSMA-PET after radical perineal prostatectomy?
How does margin positive influence your decision? 
1 Answer available
How do you manage dry eye related to Pluvicto Lu-177?
2 Answers available
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
Do you preferentially use Ra-223 first given the RALU study? 
1 Answer available
Is there a role for radiotherapy to the primary in high volume metastatic prostate cancer with well controlled disease on ADT?
1 Answer available
How do you reconcile discrepancies in clinical prostate cancer staging with AJCC and NCCN?
In particular, in the modern era of multi-parametric prostate MRI and PSMA-PET, certain findings such as EPE, SVI, or pelvic lymphadenopathy may be no...
7 Answers available
Do you cover the sacral foramen when treating pelvic lymph nodes for prostate cancer?
2 Answers available
For what duration should abiraterone be used in a patient with biochemical and pelvic node recurrence (N1M0) who had prior definitive therapy with either RP or RT?
Do you feel comfortable stopped abiraterone after 2 years? 
2 Answers available
Is there a role for prostate cancer lesion boost with EBRT in the setting of combination EBRT+ brachytherapy?
In the setting of EBRT alone, a "FLAME"-style boost may increase bPFS. Does anyone have experience with increasing the EBRT dose in combination EBRT+L...
1 Answer available
Has use of PSMA PETCT revealed increased local failures than previously known after definitive prostate EBRT with biochemical failure?
3 Answers available
How do you treat localized prostate cancer with neuroendocrine differentiation?
4 Answers available
How would you treat high risk prostate cancer in a patient with autonomic bladder dysfunction?
He cannot sense bladder fullness but has no incontinence. Intermittently he urinates by increasing intra-abdominal pressure resulting in a good stream...
1 Answer available
Do you utilize genetic testing to guide ADT for men receiving XRT for intermediate or high risk prostate cancer?
For example do you use Prolaris, or other genetic tests to guide ADT decision making? 
5 Answers available
Would you ever consider focal brachytherapy treatment in a patient who have in-prostate recurrences after RT?
Assume recurrence is biopsy proven. Would you ever consider focal vs whole gland brachytherapy? 
5 Answers available
Do you always obtain PSMA PET as initial staging for high risk and very high risk localized prostate cancer patients?
6 Answers available
Are there reasons to not use prostate SBRT when treating the prostate +\- proximal SV?
2 Answers available
Do you have recommendations after prostate RT for patients who want to conceive?
Patients in their later 40s with favorable intermediate-risk prostate cancer s/p 7000cGy/28 EBRT only.
1 Answer available
Would you consider adding abiraterone to ADT and salvage RT in a prostate cancer patient with pN1 disease at radical prostatectomy?
24 months ADT + abiraterone + definitive RT is indicated for cN1 disease but not for pN1 disease per NCCN. Can the data be extrapolated to this popula...
1 Answer available
In a patient with very high risk prostate cancer opting for prostatectomy, when, if ever, do you recommend neoadjuvant ADT?
4 Answers available
How aggressive would you be in irradiating asymptomatic bone metastases in a patient with metastatic prostate cancer?
Notably, the patient presented with renal failure due to ureteral obstruction and hydronephrosis, receives hemodialysis, and has limited systemic opti...
4 Answers available
What isotope and dose do you prefer for prostate brachytherapy monotherapy?
4 Answers available
What factors do you take into account when deciding to offer SpaceOAR to patients with prostate cancer planning to undergo radiation therapy?
For example: radiation fractionation schedule, modality (proton, MRI linac, cyberknife, etc), risk categorization, prostate size, history of IBS, hist...
6 Answers available
What is the optimal duration of ADT for unfavorable intermediate risk or high risk localized prostate cancer treated with SBRT instead of conventionally fractionated or hypofractionated RT?
Do you also give neoadjuvant, concurrent, and adjuvant ADT in the same manner as for non-SBRT EBRT?
5 Answers available
How would you treat synchronous high-risk prostate and rectal adenocarcinomas in an elderly man where the rectal cancer was resected secondary to obstruction (T3N0)?
How would you sequence therapy, and what dose and volumes would you use for radiation? Prostate cancer is localized, Gleason 4+3, PSA 65.
2 Answers available
How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?
Pretreatment PSA 25.3 with Gleason 4+3=7 and MRI suspicious for ECE. Eight months after pelvic nodal and prostate XRT to 79 Gy, PSA is 5.02 (down from...
1 Answer available
What dose constraint(s) would you use for a patient with a pelvic kidney transplant getting pelvic RT?
1 Answer available
Would you treat the prostate in a patient with widely metastatic disease who has CR to all metastatic sites after systemic therapy or ADT?
2 Answers available
Do you recommend prostate RT for patients with metastatic (M1) disease?
A recent NCBD analysis (Rusthoven et al., PMID 27325855) suggests that the addition of prostate RT significantly improves survival compared to AD...
8 Answers available
Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?
If so, how long are they on degarelix before the switch? 
2 Answers available
How would you treat pelvic node recurrence after prior RP and adjuvant XRT prostate bed only?
Would you recommend elective nodal radiation and sequential boost to the node? What dose? Would you recommend treatment similar to OLIGOPELVIS-GETUG P...
4 Answers available
What combination of clinical and pathologic features would lead you to be comfortable recommending active surveillance in a Gleason 7 prostate cancer patient?
3 Answers available
How soon after SpaceOAR placement can radiation planning CT be performed?
7 Answers available
How should the results of molecular/genetic tests for prostate cancer, be utilized in the post-prostatectomy setting?
There is a recent publication that nicely summarizes the molecular/genetic tests for prostate cancer (Ross et al., PMID 26123120). What should be done...
2 Answers available
What systemic therapy do you recommend for prostate cancer pelvic nodal recurrence on PSMA PET-CT after prostatectomy and salvage radiation?
If ADT +/- ARPI + RT, what duration of systemic therapy do you recommend?
1 Answer available
Would you omit pelvic XRT in a high risk prostate patient with negative nodal uptake on PSMA but has risk of nodal involvement >15% by nomogram?
4 Answers available
What is the recommended length for ADT in the setting of N1 disease receiving definitive radiation?
1 Answer available
How do you approach a patient with prostate cancer with sclerotic/lytic lesions found on a CT scan but not seen on a bone scan or PET-PSMA?
Would you consider these as metastatic sites? Would you biopsy to confirm?
3 Answers available
Do you hold anticoagulation prior to LDR or HDR prostate brachytherapy?
If so, when do you resume?
1 Answer available
Do you change your monitoring strategy for a high risk prostate cancer after XRT if the initial PSAs have never been very high?
4 Answers available
Does recent COVID-19 infection result in elevated PSA?
1 Answer available
How do you approach management of a patient with intermediate risk prostate cancer treated upfront with HIFU and intermittent ADT who is later found to have rising PSA and biopsy-proven prostate-confined recurrence?
Is this considered salvage or definitive since HIFU is not standard of care?   Does receipt of upfront HIFU impact ability to perform stand...
3 Answers available
Would you use abiraterone or docetaxel in addition to ADT and radiotherapy for patients with very high risk, node-negative prostate cancer?
2 Answers available
In asymptomatic patients with unfavorable intermediate risk prostate cancer and a PSA <10, how helpful/reliable and clinically useful is bone imaging?
2 Answers available
Which imaging modality do you prefer when monitoring disease status for patients with prostate cancer undergoing 177-Lu PSMA treatment?
PSMA PET vs Conventional imaging vs combined imaging?
4 Answers available
Would you recommend definitive XRT with extensive lymph node involvement of prostate cancer?
Is there an extent of nodal involvement in prostate cancer above which you would not offer definitive XRT? With PSMA/PET we see some patients with inc...
1 Answer available
How do you approach a patient with a radiographically proven recurrence in the prostate bed after prostatectomy?
If a patient who has undergone radical prostatectomy many years previously presents with biochemical failure and is found to have a nodule in the pros...
3 Answers available
In a patient with otherwise low-risk prostate cancer, does presence of a small component of Grade Group 3 disease up-stage to unfavorable intermediate?
How would you treat such a patient? 
3 Answers available
What references do you use for multi-parametric MRI delineation of the GTV in prostate cancer for prostate nodule?
Specifically, in the TZ and PZ? What references do use for prostate nodule boost as done in FLAME trial?  Hypointensities are contoured on T2W M...
2 Answers available
Do you recommend a waiting period to conceive after prostate radiation?
1 Answer available
What treatment would you offer for a patient with prior primary prostate radiation, with a biochemical progression to PSA >1.0 and negative PSMA scan?
3 Answers available
For a patient with localized high risk prostate cancer with high risk Decipher score receiving ADT and abiraterone, is there any value of continuing ADT and abiraterone beyond two years?
2 Answers available
How does a diffusely positive PSMA in the prostate affect treatment planning in a patient with MRI and biopsy showing only one area of disease?
Would you consider repeating a biopsy?
1 Answer available
Do you boost involved mesorectal nodes in node positive prostate cancer?
How high would you try to boost those involved nodes if they are in a favorable location with respect to his rectum and small bowel? 
4 Answers available
How long do you wait to start adjuvant radiation after prostatectomy?
2 Answers available
Would you consider SBRT for node negative small cell carcinoma of the prostate?
2 Answers available
What duration of ADT + abiraterone do you recommend prior to initiation of HDR brachytherapy followed by EBRT for very high risk localized cT3bN0 prostate cancer?
1 Answer available
How do you approach rising PSA many years after prostatectomy with negative PSMA PET?
4 Answers available
Would you treat the pelvis electively while treating the prostate in a setting of low volume metastatic prostate cancer?
2 Answers available
How would you manage a patient with PSA relapse 10 years after salvage radiotherapy with PSA doubling time<6 months?
Would you treat with ADT if no metastatic disease? Does absolute PSA (e.g. PSA<2) inform decision?
1 Answer available
Do you hold ADT prior to biopsy of possible prostate cancer metastatic disease?
Does ADT affect the results of a biopsy?
1 Answer available
How would you work up a patient with prostate cancer with bone scan suspicious for metastatic disease and a negative PSMA PET/CT?
Additional imaging of the potential lesions, biopsy or assume negative given normal PSMA PET/CT. 
7 Answers available
For unfavorable intermediate prostate cancer in elderly patients, would you consider radiation without ADT?
2 Answers available
How would you manage a low risk patient with a negative fusion prostate lesion by biopsy but MRI shows apparent advanced disease?
Do you allow this finding to change your management, or ignore it, as the "lesion" was not malignant?
3 Answers available
How would you treat node positive (pN+) prostate cancer with undetectable post-op PSA after radical prostatectomy and pelvic LND?
Would you offer adjuvant radiation? (Dose? Target?) vs Salvage? Would you add ADT? Would you add abiraterone? Would the number of lymph nodes involv...
3 Answers available
How do you treat a rectoprostatic fistula after prostate SBRT?
2 Answers available
How do you fractionate prostate cancer where there was rectal wall infiltration by hydrogel after healing?
3 Answers available
Would you treat a patient with metastatic castration resistant prostate cancer and prior treatment with Ra-223 with Lu-117-PSMA-617 therapy?
Is prior Ra-223 a contraindication for treatment? 
1 Answer available
What can prostate patients do for sexual function while on ADT?
4 Answers available
Would you ever recommend testosterone replacement for men with incomplete T recovery after ADT for prostate cancer?
Patient has ED unresponsive to cialis/viagra; would you recommend testosterone replacement therapy?
5 Answers available
How does urinary obstruction impact your choice of therapy for metastatic or locally advanced prostate cancer?
1 Answer available
In high or very high risk prostate cancer, do you utilize combined androgen blockade in patients receiving definitive RT?
Do you have a preference for bicalutamide? Can abiraterone be used instead?  
6 Answers available
At what PSA level would you consider restaging a patient who was treated with ADT and radiation and had undetectable PSA?
At what PSA would you become suspicious for biochemical recurrence and pursue restaging? Is there a threshold value? What imaging modality would you ...
2 Answers available
When would you use PSMA PET over conventional imaging for prostate cancer?
Would you use it for initial staging or at time of biochemical recurrence?
2 Answers available
How would you manage prostate cancer in a patient who received prior chemoradiation followed by an APR for rectal cancer?
If a patient is not a surgical candidate, what it the most appropriate treatment? 
2 Answers available
How do PSMA PET positive nodes change your treatment recommendations after RP?
Would you consider boosting the nodes?  What dose?  Would this change your recommendation for length of ADT?  
2 Answers available
How do you typically prescribe dose to a PTV for standard IMRT plans?
3 Answers available
What are your top takeaways from ASCO GU 2022?
6 Answers available
Do you consider ADT intensification with enzalutamide or abiraterone in patients receiving adjuvant radiation with ADT?
Are there clinical features (post-op PSA, Decipher score, pN+, pT3, etc) that would inform your decision?
2 Answers available
Would you offer hypofractionation to a patient in the salvage/adjuvant post-prostatectomy setting outside of a clinical trial?
Given GU003 presented at ASTRO 2021- how does this impact your recommendations for adjuvant and salvage prostate RT?
4 Answers available
Do you hold ADT before work up for prostate cancer when ordering advanced imaging such as PSMA PET?
Do you worry about false negatives on PET, CT, MRI if ADT is started before the scan? Scheduling scans can sometimes book 2-4 weeks out. 
2 Answers available
For men with intermediate or high-risk prostate cancer, can an SBRT boost be used in place of a brachytherapy boost after EBRT?
3 Answers available
Do you account for dose from previous Lu-177 treatment for definitive prostate cancer treatment?
Per lutathera information, a patient who had previous treatment for describes an estimated radiation absorbed dose of 12.8 Gy to the bladder. Would yo...
1 Answer available
How would you treat a patient with Gleason 8 or 9 prostate cancer, pretreatment PSA 15-24, with retroperitoneal adenopathy?
Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as ca...
4 Answers available
Is there an absolute PSA level above which you would not recommend a radical prostatectomy for newly diagnosed prostate cancer despite the absence of metastatic disease with advanced imaging?
Are there other high or very high risk features that would also contribute to your decision making?
1 Answer available
Would you recommend surgery or radiation for newly diagnosed localized prostate cancer diagnosed on a urethral lesion biopsy?
GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease.  Prostate MRI pending. 
2 Answers available
Will you consider adding an AR targeted agent to ADT for a patient thought to have isolated pelvic nodal recurrence of prostate CA if next generation imaging reveals additional non-regional disease not seen on conventional imaging?
Patient previously had prostatectomy and salvage RT
1 Answer available
What is the best approach to organ confined squamous cell cancer of the prostate?
Would you recommend surgery first or neoadjuvant therapy such as concurrent cisplatin/RT or another regimen?
1 Answer available
Which patients with mCRPC on ADT + advanced anti-AR do you treat with bisphosphonates or denosumab?
Did you change your practice given the SRE results in the control arm of EORTC 1333 at ASCO 2021? When using bisphosphonates or denosumab, what dosin...
2 Answers available
How exactly would you utilize ADT via leuprolide or bicalutamide with salvage RT post prostatectomy with PSA >0.5?
2 Answers available
How would you manage a patient with favorable intermediate prostate cancer patient who obtains a high Decipher test score at the end of their RT course?
Would you consider adding ADT? 
1 Answer available
Would you treat pelvic lymph nodes in your salvage prostate patient after RP without adverse features due to a limited/no pelvic lymph node sampling?
For the purpose of this question, please assume an initially undetectable post-prostatectomy PSA, no presence of positive margins, extracapsular exten...
1 Answer available
When do you use a rectal spacer in combination with radiotherapy for prostate cancer?
Are there certain situations where a hydrogel spacer is most useful based on treatment modality (SBRT, protons, brachy, etc) or other factors?
2 Answers available
How would you sequence 177LU-PSMA-617 with current therapies for men with mCRPC?
2 Answers available
Would you consider radical prostatectomy for a young male with unfavorable intermediate risk cT3a prostate cancer and PSMA PET concerning for regional lymph nodes involvement but negative conventional imaging?
Gleason 4+3=7 and PSA 4
3 Answers available
Do you consider tertiary grade pattern, LVI or PNI on prostatectomy specimens as adverse features to recommend EBRT and ADT for patients with unfavorable intermediate prostate CA after prostatectomy with undetectable PSA?
Are there other adverse features aside from seminal vesicle invasion, positive margins, or extraprostatic extension that you consider?
1 Answer available
For persistent PSA elevation after prostatectomy, would you recommend salvage radiation if pathologically negative nodes, but regional and non-regional lymphadenopathy on PSMA PET?
Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...
2 Answers available
Would you consider adding abiraterone or docetaxel in patients with high risk prostate cancer whose PSA does not become undetectable after ADT and radiotherapy with castrate level testosterone?
4 Answers available
What duration of ADT do you recommend for a patient with locally treated prostate cancer who undergoes metastasis-directed radiation therapy to a single oligometastatic bone lesion?
Would you add abiraterone or enzalutamide?
5 Answers available
How would you manage a male with a prior history of localized prostate cancer s/p radiation to prostate only (two years ago), who now presents with a T1N0 squamous cell carcinoma of the anus?
Would your management change if the prostate and lymph nodes were treated with radiation two years ago?
2 Answers available
How would you manage a patient with localized prostate cancer treated with radical prostatectomy and found to have a single involved pelvic lymph node on final pathology and a detectable postoperative PSA?
2 Answers available
Would you give abiraterone in the post-prostatectomy setting to patients with positive nodes detected at surgery?
Is there data and FDA approval for this indication? What about for nodal failure after radiation? 
1 Answer available
How would you deliver salvage prostate bed radiation in a patient with a neobladder?
What dose constraint would you use for the neobladder? Small bowel constraint of 54Gy? Or would you recommend observation or ADT alone or low dose RT ...
1 Answer available
Would you treat unfavorable intermediate risk prostate cancer in the setting of recently resected NSCLC?
How would a much higher risk cancer affect decision making? How would you treat him? 
3 Answers available
For recurrent prostate cancer after definitive radiation, how do you guide patients between the various salvage options vs ADT?
1 Answer available
What is the optimal duration of ADT for cN1 disease with EBRT?
3 Answers available
Would you offer PA nodal XRT in a patient with rising PSA and multiple PET positive nodes after previous prostate XRT treatment that is otherwise locally controlled?
For instance, if the fluclicovine scan shows a few small avid nodes not only in the pelvis but extending to the paraaortic region, would you treat the...
2 Answers available
Would you offer salvage radiation for biochemically recurrent prostate cancer with a transplanted pelvic kidney?
Will your recommendation change if there is suspicious/confirmed locally recurrent nodule in the prostate bed?
3 Answers available
Would you offer modest hypofractionation (e.g. 70 Gy/28 fractions) to a patient with intermediate risk prostate cancer and celiac disease?
1 Answer available
How do you manage androgen deprivation in a patient with oligometastatic prostate cancer in which the primary and all known metastatic sites have been treated with curative intent radiation and PSA remains undetectable?
How long would you continue androgen deprivation after radiation? 
2 Answers available
Would you recommend Radium-223 for extensive bone disease in a prostate cancer patient with adenopathy >3cm?
Per the ALSYMPCA study, they excluded patients with > 3cm lymphadenopathy. Patient is currently on enzalutamide and leuprolide and refuses docetaxe...
1 Answer available
Is there a role for docetaxel for men with high risk prostate cancer receiving radiation and androgen deprivation therapy?
Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...
4 Answers available
Do you deliver prostate SBRT every other day or consecutively?
Is there a benefit to one fractionation schedule v. the other?
3 Answers available
How would you approach an isolated prostate recurrence of high-risk prostate cancer following definitive EBRT?
4 Answers available
Is it appropriate to use photon energies above 15 MV for prostate SBRT?
Do we need to really worry about neutron contamination?
7 Answers available
In a patient who requires prostate cytoreduction prior to EBRT or brachytherapy, do you include a 5-alpha reductase inhibitor in your ADT regimen?
1 Answer available
How would the presence of active rheumatoid arthritis on methotrexate impact your choice of fractionation for a patient with prostate cancer?
1 Answer available
How do you treat newly diagnosed low volume metastatic hormone sensitive prostate cancer in light of new data from STAMPEDE presented at ESMO 2018?
Abstract LBA5_PR ‘Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCA): survival results from S...
1 Answer available
How do you determine dose for prostate SBRT?
Is there a dose response relationship, as suggested in the phase I MSKCC dose escalation study presented at ASTRO 2017?
2 Answers available
What dose and fractionation is safe to use for palliation of a large pelvic mass several years after definitive prostate brachytherapy?
1 Answer available
What is the optimal duration of ADT in high-risk prostate cancer treated with RT+ADT?
Based on the updated results of the PCS IV trial is 18 months of ADT the new standard of care for men with high-risk prostate cancer treated with...
4 Answers available
Is ADT alone appropriate for high risk prostate cancer patients without evidence of metastasis and limited life expectancy?
Is there data to support this practice, which appears in the NCCN guidelines?
1 Answer available
For what patient groups (if any) do you routinely recommend screening colonoscopy prior to radiation for prostate cancer?
3 Answers available
When do you offer salvage prostate bed RT to patients who have a biochemical recurrence >5 years after RP?
In the case of patients many years out from RP who have a slowly rising PSA, do you offer salvage RT while the PSA is still very low or follow the PSA...
1 Answer available
How do you manage musculoskeletal pain in men receiving androgen deprivation therapy for non-metastatic prostate cancer?
In patients with new bone pain and without any evidence of bone metastases receiving GnRH agonists, how do you manage pain symptoms?
1 Answer available
If a patient with non-metastatic prostate cancer is found to have a BRCA mutation, should this influence treatment recommendations for local therapy?
2 Answers available
What is your approach to patients with locally recurrent prostate cancer following cryotherapy or HIFU?
With biopsy-proven, negative systemic restaging disease, what dose and fractionation is appropriate if treating with IMRT? Should ADT generally b...
1 Answer available
Does a transitional zone vs. peripheral zone location of low risk prostate cancer affect your recommendation for active surveillance?
1 Answer available
Do you treat pelvic lymph nodes in patients with high-risk prostate cancer who refuse ADT?
Would you consider this an indication to treat lymph nodes, if you would typically not do so?
2 Answers available
Should definitive radiotherapy and ADT be offered to patients with PSA > 100 who have no evidence of metastatic disease?
Is there an upper limit to offer definitive RT? Is it possible to have a PSA of 100-500 and still have only local disease?
6 Answers available
How do you approach isolated recurrence in a para-aortic lymph node following definitive radiation for localized prostate cancer?
Is there a role for salvage LN dissection or salvage RT to the node? And is there a role for systemic therapy (ADT or chemotherapy) in addition? If yo...
1 Answer available
What imaging workup should be completed in patients with a detectable PSA following prostatectomy?
Should the workup change with the PSA level (for example, >2 vs <2 ng/ml post-op PSA)?  Is there a PSA level for which salvage radiotherapy...
2 Answers available
Do you counsel patients on the risk of dementia following androgen deprivation therapy for prostate cancer?
Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding ...
3 Answers available
When do you initiate androgen deprivation therapy for biochemical relapse of prostate cancer following primary therapy?
Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ev...
1 Answer available
Do you treat with high-dose radiation alone (without ADT) for favorable intermediate risk prostate cancer?
If so, what criteria do you use to guide your decision?
3 Answers available
How do you define PSA progression after salvage or adjuvant prostate fossa radiotherapy?
In the recent 10 year update of the ARO (adjuvant pelvic RT versus observation) trial, their definition of PSA failure was 2 successive rise...
3 Answers available
What duration of androgen deprivation therapy do you use for patients with pN+ prostate cancer undergoing upfront adjuvant RT after a radical prostatectomy and pelvic lymph node dissection?
Do other factors (i.e. Gleason score, pretreatment PSA, or pT stage) affect your decision? 
2 Answers available
Which, if any, aspects of your management of prostate cancer differ in your African-American patients versus those of other racial/ethnic backgrounds?
Given recent advancements in the understanding of biological differences in prostate cancer patients of African vs. other ancestry, does your manageme...
1 Answer available
At what PSA do you initiate ADT for a biochemical recurrence after prostate radiotherapy (adjuvant, salvage, or definitive)?
Does PSADT play a factor in your decision-making? If so, how specifically?  I've tended to wait until the PSA is 10-15, re-image, and then begin...
1 Answer available
For patients eligible for and considering active surveillance for low-risk prostate cancer, do you routinely use tests for molecular risk stratification?
Are there specific subsets for whom these results should change management?
1 Answer available
Which PET imaging modality, if any, is preferred to work up possible nodal involvement or local recurrence in prostate cancer?
In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involve...
1 Answer available
When should intermittent androgen deprivation vs continuous androgen deprivation be used for the treatment of prostate cancer?
 In a patient with node positive disease, treated definitively with radiation, should continuous or intermittent ADT be administered? If a patien...
1 Answer available
When does a rising PSA after prostatectomy indicate growth just of normal prostate?
Guidelines dont seem to account for this possibility. Could it just be normal prostate tissue growing back that is leading to PSA, why just assume it ...
1 Answer available
How do you manage high risk prostate cancer patients with well controlled Crohn's disease?
Do you offer RT if the patient is well controlled on medications?
2 Answers available
What are the most common errors that can be made when performing prostate SBRT?
In starting prostate SBRT at an instutution, what are issues with the treatment that one should pay special attention to?
2 Answers available
At what point would Radium-223 dicholoride treatment be the best management for a patient with established metastatic prostate cancer with an elevated PSA and symptomatic bone pain with corresponding bone lesions on imaging?
1 Answer available
For biochemical failure following prostatectomy, is there a PSA value that would be considered too high to offer local salvage radiotherapy?
On what other factors should be considered in making a treatment recommendation for salvage radiation therapy?
3 Answers available
When should SBRT be offered to oligometastatic bone disease in a patient with prostate cancer?
What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...
2 Answers available
At what PSA do you start calculating doubling time post-prostatectomy?
With ultra-sensitive PSA, it's unclear to me whether a doubling from 0.01 to 0.02 or 0.02 to 0.04 is significant. Is there a certain value that you wo...
1 Answer available
How long should the duration of hormones be in post-prostatectomy patients receiving salvage RT?
If a patient is deemed high risk enough to require hormones with RT in the salvage setting, how long would you maintain them on ADT? Would you extrapo...
2 Answers available
Do you forgo adjuvant radiotherapy for men with pT3 prostate cancer who have significant urinary incontinence?
Would you favor only offering salvage therapy if the PSA rises?
5 Answers available
What is the best toxicity data to quote to patients for prostate IMRT vs nerve-sparing prostatectomy?
When counseling patients with organ-confined prostate cancer, what rates of impotence, incontinence, rectal toxicity, and urethral stricture shou...
2 Answers available
What is the minimum amount of time you should wait between a TURP and the start of definitive prostate radiation therapy?
2 Answers available
Should prostate cancer genomic classifiers, such as Decipher, be used in all high risk post-prostatectomy patients to risk stratify patients to adjvant RT vs PSA observation and possible salvage RT?
The optimal timing of post-prostatectomy RT in high-risk patients is debatable and currently the question of prospective randomized trials; however, g...
1 Answer available
What is the appropriate treatment for a low lying rectal cancer in the setting of prior definitive prostate IMRT?
Fore example for a T3N0 rectal cancer on EUS?
1 Answer available
What is the best approach to management of newly diagnosed intermediate or high risk prostate cancer in a patient with high grade non-muscle invasive bladder cancer?
In this case, the patient is currently on maintenance BCG.
1 Answer available
Do you feel that HDR brachytherapy alone is adequate treatment for some intermediate-risk prostate cancer patients?
If so, what selection criteria do you use for such patients?
2 Answers available
For which patients with localized prostate cancer is SBRT an alternate standard of care?
1 Answer available
Is there an age that is too young for prostate irradiation?
Do you use a particular cut-off? For example, someone in their 40's?
3 Answers available
Would you treat radio-graphically positive pelvic lymph nodes when palliating a patient with metastatic patient prostate cancer and obstructive symptoms?
The patient has a positive bone scan (2 lesions), grade 4+5=9/10 prostate, and cancer cannot urinate without a catheter.
1 Answer available
Should prophylactic breast radiotherapy still be practiced for patients with prostate cancer taking bicalutamide?
1 Answer available
For intermediate risk prostate cancer do you recommend short-term complete androgen blockade or LHRH agonist alone?
 
2 Answers available
If one decides to use a mpMRI to stage a pt with low-risk prostate cancer, how do you work up a focal lesion suspicious for higher grade GS 7-10 disease?
1 Answer available
Which patients with intermediate and high risk prostate cancer should not receive androgen deprivation therapy?
More specifically, which cardiac risk factors do you look for? Diabetes? Previous MI? Dyslipidemia? Peripheral vascular disease? CHF?
2 Answers available
For patients with high risk prostate cancer, is there data to support increased morbidity, such as increased urethral strictures or cystitis, when given postprostatectomy XRT as opposed to definitive XRT?
In general how do you counsel patients with high risk prostate cancer when choosing radiation verse prostatectomy? What numbers do you quote for ...
4 Answers available
Would you consider offering salvage radiation to a patient with castrate resistant prostate cancer who has never had local therapy and has no evidence of lymph node or distant metastasis?
This is a patient who would have been an appropriate candidate for radiation upfront, but was managed with androgen deprivation therapy instead. On th...
2 Answers available
If a daily conebeam CT is done for prostate cancer treatments, do you subtract any treatment fractions to compensate for the daily imaging dose?
1 Answer available
What is your technique for CT and MRI fusion for external beam prostate planning?
Sometimes the scans don’t line up well because of differences in rectal and bladder fullness- any tips to optimize the fusion?
1 Answer available
Would you treat a patient who failed cryotherapy?
1 Answer available
For patients with high risk prostate cancer, is there data to support prostatectomy, as opposed to upfront RT?
I ask this because I am seeing more and more patients who have had surgery despite presenting with high risk disease.
1 Answer available
In a low volume prostate cancer (2 of 12 cores, low percentage) with a GS 4+4=8, how long does ADT need to be administered?
1 Answer available
What criteria do you use in deciding whether or not to treat the pelvis in prostate cancer?
I know many do not treat the pelvis at all, but for those who do, what criteria do you use? Risk? Gleason? PSA? T stage?
1 Answer available
What fractionation and dose constraints do you use for prostate SBRT?
1 Answer available
Do you decrease the duration of hormones in a man with high risk prostate cancer and cardiac risk factors?
3 Answers available
What's the safest way to hypofractionate treatment for prostate cancer?
1 Answer available
What is your management strategy for patients with positive lymph nodes after radical prostatectomy?
2 Answers available
Do HIV/AIDS patients with prostate cancer have increased radiation toxicity?
And should special precautions be taken (such as dose reduction, prophylactic symptom management, etc)?
1 Answer available
What is your institution's active surveillance protocol?
1 Answer available
How should I interpret a Gleason 7 prostate cancer (4+3 or 3+4) with tertiary grade 5?
Would you treat this as high risk?
1 Answer available
Is there any data to support the use of hormone therapy with RT in the adjuvant post-prostatectomy setting?
1 Answer available


Papers discussed in this category

International journal of radiation oncology, biology, physics, 2005-04-01
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Int J Radiat Oncol Biol Phys, 2005 Sep 1
Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy.
International journal of radiation oncology, biology, physics, 2004-06-01
Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
International journal of radiation oncology, biology, physics, 2007-08-01
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
International journal of radiation oncology, biology, physics, 2014-04-01
Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys., 2012-12-01
Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer.
European urology, 2013-12
A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.
CA Cancer J Clin, 2010 May-Jun
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
J Natl Cancer Inst, 2010 Jan 6
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
BJU international, 2014-12
The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
JAMA, 2011-12-07
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Cancer, 2013 May 15
Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.
International journal of radiation oncology, biology, physics, 2010-11-01
Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
American journal of clinical oncology, 2016-02
Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey.
Radiother Oncol, 2013-01-01
Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-03-20
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.
Eur. Urol., 2009-05-01
Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
The American journal of surgical pathology, 2005-09
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
The New England journal of medicine, 2012-07-19
Radical prostatectomy versus observation for localized prostate cancer.
BMJ, 2014-01-08
Prostate cancer: summary of updated NICE guidance.
International journal of radiation oncology, biology, physics, 2012-05-01
Matched cohort analysis of outcomes of definitive radiotherapy for prostate cancer in human immunodeficiency virus-positive patients.
International journal of radiation oncology, biology, physics, 2012-02-01
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
N. Engl. J. Med., 2009-06-11
Duration of androgen suppression in the treatment of prostate cancer.
JAMA, 2006-11-15
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
Practical radiation oncology, 2013
Late toxicity after intensity modulated and image guided radiation therapy for localized prostate cancer and post-prostatectomy patients.
N Engl J Med, 2008 Mar 20
Quality of life and satisfaction with outcome among prostate-cancer survivors.
The Journal of urology, 2011-09
Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.
Practical radiation oncology, 2013
Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life.
Urologic oncology, 2014-04
Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer.
BJU international, 2014-03
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10
Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
J. Urol., 1998-01-01
Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study.
Eur. Urol., 2014-03-01
Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy.
BJU international, 2015-10
Preoperative predictive model of recovery of urinary continence after radical prostatectomy.
The New England journal of medicine, 2011-07-14
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
International journal of radiation oncology, biology, physics, 2010-04
Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
JAMA, 2015
Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-06-20
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
The Journal of urology, 2012-01
High dose brachytherapy as monotherapy for intermediate risk prostate cancer.
Cancers, 2022 Jan 29
Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review.
International journal of radiation oncology, biology, physics, 2013-03-15
Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Cancer, 2014-06-15
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease.
Cancer, 2006 Jun 15
Does age matter in the selection of treatment for men with early-stage prostate cancer?
International journal of radiation oncology, biology, physics, 2003-03-15
Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.
Urology, 2008-11
CounterPoint: second malignancies after radiotherapy for prostate cancer: keeping perspective.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-05-15
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
American journal of clinical oncology, 2014-06
Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review.
International journal of radiation oncology, biology, physics, 2011-07-15
External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS).
International journal of radiation oncology, biology, physics, 2010-07-15
External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.
Frontiers in oncology, 2011
Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999-04
Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-20
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.
The New England journal of medicine, 2017-02-02
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
JAMA Oncol, 2017-10-01
Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.
Seminars in radiation oncology, 2013-07
Adjuvant versus salvage radiotherapy for high-risk prostate cancer patients.
Eur Urol, 2015 Jul 16
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.
BJU Int, 2009 Feb
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
European urology, 2014-06
Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-20
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
The New England journal of medicine, 2013-07-18
Alpha emitter radium-223 and survival in metastatic prostate cancer.
JAMA Oncol, 2020 Aug 27
Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review.
Lancet, 2016 Mar 19
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
European urology, 2011-04
The prognostic significance of capsular incision into tumor during radical prostatectomy.
Urology, 2001-11
Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20
Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.
J. Nucl. Med., 2015 Jun 25
Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Int. J. Radiat. Oncol. Biol. Phys., 2015 Apr 23
Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy.
Brachytherapy, 2020 Apr 21
Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.
Int. J. Radiat. Oncol. Biol. Phys., 2020 Jan 24
Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-01
Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.
Lancet Oncol., 2010-02-01
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20
Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.
The Journal of urology, 2005-08
Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer.
Mol Clin Oncol, 2015 May 04
Bee pollen and honey for the alleviation of hot flushes and other menopausal symptoms in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-12-10
Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-10
Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.
The Journal of urology, 1999-07
Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 2009-03
A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).
Mayo Clin Proc, 2004 Oct
Pilot evaluation of paroxetine for treating hot flashes in men.
JNCI Cancer Spectr, 2019 Oct 21
Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).
N Engl J Med, 1994 Aug 11
Megestrol acetate for the prevention of hot flashes.
The New England journal of medicine, 2018-05-03
Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-01
Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-20
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
The Journal of urology, 2002-09
Impact of previous local treatment for prostate cancer on subsequent metastatic disease.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-01-15
Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.
Nature, 2005-12-08
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
J Clin Oncol, 1999 Jul
Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.
Lancet, 2015 Jan 3
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.
The New England journal of medicine, 2001-12-06
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Lancet, 2001-09-22
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
Breast Cancer Res. Treat., 2010-02-01
Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature.
The Journal of urology, 1982-06
Treatment of a metastatic prostate derived tumor with surgery and chemotherapy.
Cancer research, 2000-04-15
Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction.
J. Clin. Oncol., 2009-04-01
Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer.
Oncol. Rep., 2015-12-01
Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer.
Nat Commun, 2015-04-01
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.
PLoS ONE, 2016-01-01
Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?
J. Urol., 2002-04-01
Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
Lancet Oncol., 2015 Sep 09
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
European urology, 2018-02
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
Lancet, 2018 Oct 18
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
The New England journal of medicine, 2015-08-20
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
JAMA, 2008-06-18
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
International journal of radiation oncology, biology, physics, 2007-11-01
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
The Lancet. Oncology, 2006-06
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20
Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-20
Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.
JAMA oncology, 2016-04
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.
JAMA oncology, 2017-01-01
Association Between Androgen Deprivation Therapy and Risk of Dementia.
Int J Radiat Oncol Biol Phys, 2012 Jul 15
Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen.
International journal of radiation oncology, biology, physics, 2011-06-01
Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.
Lancet, 2008 Dec 16
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Lancet, 2011-12-17
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
Urology, 2017-04
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.
Eur Urol Oncol, 2020 May 22
PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy.
Int J Radiat Oncol Biol Phys, 1986 Mar
Extended field (periaortic) irradiation in carcinoma of the prostate--analysis of RTOG 75-06.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10
External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10
Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.
JAMA Oncol,
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
J Urol,
Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.
Frontiers in oncology, 2017
Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
International journal of radiation oncology, biology, physics, 2008-09-01
Intrafractional motion of the prostate during hypofractionated radiotherapy.
European urology, 2018-07
Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
International journal of radiation oncology, biology, physics, 2008-04-01
Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
International journal of radiation oncology, biology, physics, 2014-07-01
Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer.
International journal of radiation oncology, biology, physics, 2016-07-01
Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013-11
Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20
Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.
Frontiers of radiation therapy and oncology, 2011
Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial.
Semin Radiat Oncol, 2016 Aug 31
Options for Salvage of Radiation Failures for Prostate Cancer.
International journal of radiation oncology, biology, physics, 2018-06-01
Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
J. Clin. Oncol., 2015 May 26
Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.
J. Clin. Oncol.,
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.
International journal of radiation oncology, biology, physics, 2012-04-01
High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with Cerrobend vs. MLC SFGRT.
Brachytherapy, 2016
Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.
J Clin Oncol, 2021 Jan 26
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.
J Clin Oncol, 2021 Jan 20
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
Lancet, 2021 Dec 23
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Practical radiation oncology, 2018
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.
Practical radiation oncology, 2018
A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.
International journal of radiation oncology, biology, physics, 2008-01-01
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.
Frontiers in oncology, 2014
Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose-Escalation Study.
International journal of radiation oncology, biology, physics, 2017-04-01
Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.
The Journal of urology, 2004-03
High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
International journal of radiation oncology, biology, physics, 2018-10-01
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
Journal of contemporary brachytherapy, 2016-10
Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
International journal of radiation oncology, biology, physics, 2012-07-01
Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.
Radiother Oncol, 2009 Apr
Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy.
Semin Radiat Oncol, 2004-01-01
Errors and margins in radiotherapy.
Practical radiation oncology, 2017
State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions.
The Lancet. Oncology, 2019-03
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
N. Engl. J. Med., 2017-07-27
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Eur. Urol., 2018 Jul 03
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
Lancet, 2019 Apr 11
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
J. Clin. Oncol., 2017 Dec 14
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Eur. Urol., 2019 Jul 19
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
Ann. Oncol.,
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01
Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
Urology, 2001-08
Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.
BMC Cancer, 2014 Sep 15
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.
JAMA Oncol,
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Lancet Oncol., 2016-06-01
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
JAMA Oncol, 2020 Mar 26
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.
Lancet, 2020 Sep 28
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Lancet Oncol,
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Lancet Oncol,
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
The New England journal of medicine, 2017-07-27
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
JAMA Oncol, 2021 Feb 18
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Radiother Oncol, 2020 Apr 01
Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.
The Lancet. Oncology, 2012-02
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.
International journal of radiation oncology, biology, physics, 2016-11-01
Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Cancer, 2018-07-15
Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
Urology, 2000-11-01
Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.
Abdom Radiol (NY), 2019 Aug 29
Apical periurethral transition zone lesions: MRI and histology findings.
Lancet, 2021 May 07
F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
N. Engl. J. Med., 2016-10-13
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
J Urol, 2020 Apr 13
Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.
Eur J Nucl Med Mol Imaging, 2020 Aug 12
Pelvic lymph-node staging with F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
J Urol,
Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.
Lancet Oncol, 2010 Oct 07
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-10
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
Prostate Cancer Prostatic Dis, 2020 May 13
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
The Lancet. Oncology, 2018-11
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Pancreas, 2010-08
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.
European urology, 2018-08
Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
American journal of clinical and experimental urology, 2014
Neuroendocrine differentiation of prostate cancer: a review.
The Prostate. Supplement, 1998
Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
The Prostate, 2001 May 15
Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
Clinical nuclear medicine, 2017 Jan
PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer.
The New England journal of medicine, 2018-04-12
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
The New England journal of medicine, 2018-06-28
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
The New England journal of medicine, 2019-03-28
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Clin Cancer Res, 2019 Sep 11
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Lancet Oncol, 2019 Oct 16
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
JAMA Oncol,
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
J Urol, 2021 Feb 26
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-01
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
International journal of radiation oncology, biology, physics, 2015-06-01
Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126.
International journal of radiation oncology, biology, physics, 2017-06-01
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
Proceedings of the National Academy of Sciences of the United States of America, 2011-06-07
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017-01
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
European journal of nuclear medicine and molecular imaging, 2018-11
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
European urology oncology, 2018-05
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
J Nucl Med, 2021 Dec 16
Predictors of F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
J Nucl Med, 2018 Dec 14
Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.
Eur J Nucl Med Mol Imaging, 2019 Nov 15
The effect of androgen deprivation therapy on Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.
Eur J Nucl Med Mol Imaging, 2019 Dec 26
Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer.
JAMA Oncol,
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
J Urol, 2021 Feb 03
The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
J Nucl Med, 2020 Jan 10
Impact of Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.
Clin Cancer Res, 2021 Feb 23
Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.
Lancet, 2020 Sep 28
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
BMC cancer, 2019-06-13
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
J Clin Oncol, 2022 Mar 15
Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.
Am J Clin Oncol,
Pelvic Reirradiation Utilizing Pulsed Low-dose Rate Radiation Therapy.
Prostate, 2022 Jun 08
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
International journal of radiation oncology, biology, physics, 2006-07-15
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
J Nucl Med, 2021 Jun 24
Lu-Prostate-Specific Membrane Antigen Ligand After Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience.
Oncotarget, 2017 Feb 25
Radioligand therapy of metastatic prostate cancer using Lu-PSMA-617 after radiation exposure to Ra-dichloride.
Practical radiation oncology, 2017
Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall.
Urologic oncology, 2017-04
An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
Radiology, 2019-03
A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.
J Clin Oncol, 2014 Dec 15
Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
BJU Int, 2020 Feb 12
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
JAMA Oncol,
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.
BJU Int, 2022 Apr 03
Development and validation of a life expectancy calculator for US patients with prostate cancer.
Int J Radiat Oncol Biol Phys, 2020 Sep 11
Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
Lancet Oncol, 2022 Jan 17
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
Prostate Int, 2019 Feb 22
The role of prostate-specific antigen density in men with low-risk prostate cancer suitable for active surveillance: results of a prospective observational study.
J Urol, 2019 Sep 06
Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
Lancet,
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
AJR Am J Roentgenol, 2022 Jun 29
Head-To-Head Comparison of Ga-PSMA-11 PET/CT and Tc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis.
Eur Radiol, 2022 Aug 08
Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.
Urology,
Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.
Clin Nucl Med,
Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System.
Skeletal Radiol, 2014 May 20
Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.
Eur J Nucl Med Mol Imaging,
The flare phenomenon: still learning after 35 years.
Journal of vascular and interventional radiology : JVIR, 2019 Aug 01
Prostatic Artery Embolization Obviates the Need for Androgen Deprivation Therapy prior to Stereotactic Body Radiation Therapy in Prostate Cancer.
European urology, 2019-09
Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.
Radiother Oncol, 2018 May 03
Contouring of prostate tumors on multiparametric MRI: Evaluation of clinical delineations in a multicenter radiotherapy trial.
Int J Radiat Oncol Biol Phys, 2016 Apr 21
Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion.
AJR Am J Roentgenol, 2020 Sep 02
Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection.
Radiology, 2020 Apr 21
Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel.
International journal of radiation oncology, biology, physics, 2019-06-01
Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Eur Urol, 2021 Apr 03
Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.
International journal of radiation oncology, biology, physics, 1998-03-01
Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06.
Front Oncol, 2022 Jun 07
Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With Lymph Node-Positive Prostate Cancer.
Eur Urol, 2022 Jul 27
Re: Pawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2022;82:82-96.
Lancet Oncol,
Considering benefit and risk before routinely recommending SpaceOAR.
Radiother Oncol, 2020 Oct 07
Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.
Int J Radiat Oncol Biol Phys, 2015 Dec 23
Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer.
Int. J. Radiat. Oncol. Biol. Phys., 2017-06-01
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Radiother Oncol, 2012 Feb 16
Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
AJR Am J Roentgenol, 2021 Jan 21
Diagnostic Accuracy of Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.
Eur Urol, 2021 Jul 08
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
Eur Urol Focus, 2021 Mar
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.
Adv Radiat Oncol, 2022 Jul 28
Salvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure.
J Urol, 2019 01
Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.
International journal of radiation oncology, biology, physics, 2010-06-01
Incidental testicular irradiation from prostate IMRT: it all adds up.
International journal of radiation oncology, biology, physics, 2012-01-01
Testicular doses in image-guided radiotherapy of prostate cancer.
Targeted oncology, 2023 Apr 15
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
Urology, 2021 Oct 06
Variation of Serum PSA Levels in COVID-19 Infected Male Patients with Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Studys.
Adv Urol, 2011 Oct 16
Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?
Eur Urol, 2009 Dec 18
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Practical radiation oncology, 2015
Permanent prostate brachytherapy using high V150.
JAMA, 2005-09-14
Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
JAMA oncology, 2018-06-14
Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
Int J Radiat Oncol Biol Phys, 2021 Nov 03
Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).
Eur Urol, 2021 Dec 23
Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.
Int J Radiat Oncol Biol Phys, 2000 Sep 01
Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients.
Radiother Oncol, 2021 Feb 13
Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy.
J Clin Oncol, 2023 Apr 27
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.
Front Oncol, 2022 Mar 29
Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study.
Brachytherapy, 2022 May 04
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer.
Pract Radiat Oncol, 2023 Jul 11
A Phase I Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.
Pract Radiat Oncol, 2021 May 30
Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation.
Scandinavian journal of urology and nephrology, 2004
Does brachytherapy of the prostate affect sperm quality and/or fertility in younger men?
BJU international, 2005-10
New life after prostate brachytherapy? Considering the fertile female partner of the brachytherapy patient.
Andrologia, 2017-02
Successful sperm extraction and live birth after radiation, androgen deprivation and surgical castration for treatment of metastatic prostate cancer.
Current opinion in urology, 2007 Nov
Therapeutic testis biopsy for sperm retrieval.
N Engl J Med, 2021 Jun 23
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Lancet, 2019 Jun 18
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Int J Radiat Oncol Biol Phys, 2015 Jul 15
A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer.
J Clin Oncol, 2019 Dec 12
Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.
J Clin Oncol, 2021 Jan 10
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
J. Clin. Oncol., 2016-05-20
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.
Lancet Oncol., 2018 Dec 19
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Lancet Oncol, 2015 Feb 19
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Eur J Cancer, 2020 Dec 03
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.
Pract Radiat Oncol, 2022 Mar-Apr
Feasibility of Same-Day Prostate Fiducial Markers, Perirectal Hydrogel Spacer Placement, and Computed Tomography and Magnetic Resonance Imaging Simulation for External Beam Radiation Therapy for Low-Risk and Intermediate-Risk Prostate Cancer.
Prostate, 2020 Feb
Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
BJUI Compass, 2021 Jan 05
Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.
Lancet, 2022 Apr 08
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Eur Urol, 2018 Sep 25
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Eur Urol, 2015 May 21
Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.
JAMA oncology, 2023 Jun 01
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.
International journal of radiation oncology, biology, physics, 2019-08-01
Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.
Lancet, 2021 Feb 11
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Eur J Nucl Med Mol Imaging, 2023 Jul 05
The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [Ga]Ga-PSMA-11-PET/CT in high-risk prostate cancer patients treated with definitive radiotherapy.
BJU Int, 2021 Dec 13
The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography.
J Urol, 2021 Jan 27
Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
Eur Urol, 2020 Jan 08
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study.
Int J Radiat Oncol Biol Phys, 2019 Oct 10
Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy.
EJNMMI physics, 2023 Feb 09
Investigation of image-based lesion and kidney dosimetry protocols for Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition.
Lancet Oncol, 2019 Sep 17
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Lancet Oncol, 2021 Feb
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
The Lancet. Oncology, 2022 Sep 13
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Radiother Oncol, 2018 Jan 11
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.
Brachytherapy, 2022 Apr 06
Brachytherapy focal dose escalation using ultrasound based tissue characterization by patients with non-metastatic prostate cancer: Five-year results from single-center phase 2 trial.
International journal of radiation oncology, biology, physics, 2022 Dec 15
An Updated Analysis of the Survival Endpoints of ASCENDE-RT.
JAMA oncology, 2023 Mar 01
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
JAMA oncology, 2024 Jul 01
Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer.
Practical radiation oncology, 2024 Jul 15
Target Volume Optimization for Localized Prostate Cancer.
The Lancet. Oncology, 2014-05
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
The New England journal of medicine, 2023 Oct 19
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Health and quality of life outcomes, 2020 May 12
How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods.
European urology, 2015 Feb 14
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
International journal of cancer, 2022 May 16
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022 Oct 27
Safety and Survival Outcomes of Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior Ra treatment: The RALU Study.
Annals of oncology : official journal of the European Society for Medical Oncology, 2024 May 09
Adjuvant versus salvage radiotherapy: debates will be reignited.
European urology, 2022 Apr 18
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
The New England journal of medicine, 2018-05-10
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
The New England journal of medicine, 2020 Mar 05
MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
Int J Radiat Oncol Biol Phys, 2019 Oct 17
Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.
International journal of radiation oncology, biology, physics, 2024 Feb 28
A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020 Jan 10
Management of Patients with Renal Failure Undergoing Dialysis During I Therapy for Thyroid Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023 Jun 08
SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-PSMA-617 Radionuclide Therapy.
The New England journal of medicine, 2023 Mar 11
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Eur Urol, 2020 Dec 10
A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
International journal of radiation oncology, biology, physics, 2019-08-01
Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.
European urology oncology, 2021 May 18
Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Nov 11
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
NEJM evidence, 2023 Oct 22
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
CA: a cancer journal for clinicians, 2017-03
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021 Sep 02
A Comparison of F-DCFPyL, F-NaF, and F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer.
Lancet (London, England), 2020 Mar 22
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021 May 14
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
European urology oncology, 2020 Jun 24
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
BMC Cancer, 2020 May 12
PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
La Radiologia medica, 2021 Nov 30
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting.
European urology, 2023 Jul 05
Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
The Journal of urology, 2023 Apr 26
Diagnostic Performance and Safety of F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
International journal of radiation oncology, biology, physics, 2010-02-01
Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations.
JAMA, 2008-01-23
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
International journal of radiation oncology, biology, physics, 2016-11-15
Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.
JAMA network open, 2020 Sep 01
Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable: A Secondary Analysis of the RTOG 9408 Randomized Clinical Trial.
The Prostate, 2023 May 27
First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer.
Lancet Oncol, 2016 Aug
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Clinical oncology (Royal College of Radiologists (Great Britain)), 2016 Sep 29
Twenty Fraction Prostate Radiotherapy with Intra-prostatic Boost: Results of a Pilot Study.
Radiation oncology (London, England), 2012-06-09
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy.
Radiother Oncol, 2021 Dec 28
Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial.
Int J Radiat Oncol Biol Phys, 2024 Jan 1
Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer.
International journal of radiation oncology, biology, physics, 2022 Aug 17
The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 25
Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial.
International journal of radiation oncology, biology, physics, 2022 Jun 05
Mature Local Control and Reirradiation Rates Comparing Spine Stereotactic Body Radiation Therapy With Conventional Palliative External Beam Radiation Therapy.
BMC Cancer, 2019 Aug 19
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
BMC Cancer, 2020 May 5
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Chest, 2007-07
Natural history of stage I non-small cell lung cancer: implications for early detection.
The Journal of urology, 2017-08
An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015 Feb 17
Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.
European urology, 2021 Aug 28
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
European urology oncology, 2021 Apr 10
Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
European urology, 2021 Dec 06
Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography.
The Journal of urology, 2024 Jun 17
Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prospective, Single-Arm Trial.
International journal of radiation oncology, biology, physics, 2000-02-01
Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers.
International journal of radiation oncology, biology, physics, 2009 Nov 10
Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
Acta oncologica (Stockholm, Sweden), 2005
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
Seminars in radiation oncology, 2004 Jan
Effects of motion on the total dose distribution.
Radiation oncology (London, England), 2015-10-24
Passive proton therapy vs. IMRT planning study with focal boost for prostate cancer.
International journal of radiation oncology, biology, physics, 2024 Sep 01
Point: Rectal Spacer Use is Recommended for All Prostate Cancer Radiation Therapy Fractionation Regimens.
International journal of radiation oncology, biology, physics, 2024 Sep 01
Counterpoint: The Perplexing Prevalence of Hydrogel Spacer Devices: We Simply Don't Need Them.
International journal of radiation oncology, biology, physics, 2024 Sep 26
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer.
The Prostate, 2023 Mar 22
Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001-09 prospective registry trial.
European urology, 2023 Apr 07
Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
Radiology, 2019 Sep 10
Diagnostic Accuracy of Multiparametric MRI versus Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.
Radiother Oncol, 2018 May
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
Radiother Oncol, 2023 Aug
From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial.
The New England journal of medicine, 2024 Oct 17
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
European urology, 2024 Sep 11
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.

Related Topics in Radiation Oncology

Copyright © 2024 theMednet
All Rights Reserved.